Telehealth

How Telehealth GLP-1 Platforms Decide If You Qualify for a Prescription

7 min read · Published 04-26-2026 · Sources cited to FDA / NIH / clinical trials

Telehealth GLP-1 platforms decide whether you qualify by checking a short list of FDA-approved criteria — primarily your body mass index (BMI) and whether you have at least one weight-related health condition. A licensed clinician reviews your intake form, health history, and sometimes lab results before any prescription is written. No platform can legally skip that clinician step.

What Are the FDA-Approved Criteria for GLP-1 Medications?

Every telehealth clinician is bound by the same FDA labeling that governs in-person prescribers. The thresholds differ slightly by drug:

  • Wegovy (semaglutide 2.4 mg): BMI ≥ 30, or BMI ≥ 27 with at least one weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. (FDA Wegovy labeling, 2021.)
  • Zepbound (tirzepatide): Same BMI thresholds as Wegovy. (FDA Zepbound labeling, 2023.)
  • Ozempic and Mounjaro: Approved specifically for type 2 diabetes management, so prescribers must document a diabetes diagnosis when using these drugs on-label.

Off-label prescribing is legal but must still be clinically justified in the patient record. A responsible telehealth platform will document the rationale clearly.

Most important point: A BMI at or above 30 — or at or above 27 with a qualifying condition — is the core FDA threshold every telehealth platform uses to evaluate GLP-1 eligibility. If you don't meet this threshold, a legitimate platform will not issue a prescription.

What Does the Intake Process Actually Look Like?

Most platforms follow a similar sequence, even if the branding differs. Here is what you can typically expect from first click to prescription decision:

Step What Happens Typical Timeframe
1. Eligibility screener You enter height, weight, and basic health info. The platform auto-calculates BMI and flags obvious disqualifiers. 5–10 minutes
2. Medical intake form Detailed questions about current medications, diagnoses, allergies, family history of thyroid cancer, and past weight-loss attempts. 10–20 minutes
3. Clinician review A licensed physician, NP, or PA reads your responses. Some platforms offer synchronous video visits; others use asynchronous review. Same day to 48 hours
4. Lab review (if required) Clinician may request recent bloodwork (HbA1c, lipids, kidney function) or order labs through a partner lab. 1–5 business days
5. Prescription decision Approved: prescription sent to pharmacy or compounding partner. Denied: clinician explains why and may suggest alternatives. After steps 3–4 complete
6. Follow-up check-ins Ongoing messaging or scheduled visits to monitor side effects and assess dose escalation. Every 4–12 weeks

What Health Conditions Can Help You Qualify at a Lower BMI?

If your BMI falls between 27 and 29.9, a qualifying comorbidity is required under FDA labeling. Telehealth clinicians look for documentation or self-report of:

  • Type 2 diabetes or prediabetes — the most commonly documented comorbidity in GLP-1 cases.
  • Hypertension — either diagnosed by a provider or supported by blood pressure readings you provide.
  • Dyslipidemia — elevated LDL, low HDL, or high triglycerides shown on recent labs.
  • Obstructive sleep apnea — a diagnosis letter or CPAP prescription is often accepted as documentation.
  • Cardiovascular disease — history of heart attack, stroke, or atherosclerosis may also qualify.

Research published by Ryan and Yockey in Current Obesity Reports (2017) confirms that even modest weight loss of 5–10% can meaningfully improve these conditions, which is part of the clinical rationale for treating patients in this BMI range.

What Can Disqualify You From a Telehealth GLP-1 Prescription?

Certain conditions are listed as contraindications or warnings in FDA labeling, and a responsible telehealth clinician will screen for them carefully:

  • Personal or family history of medullary thyroid carcinoma (MTC) — a black-box warning on all GLP-1 receptor agonists.
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) — also carries a black-box warning.
  • History of pancreatitis — FDA labeling flags an elevated risk; clinicians weigh this carefully.
  • Pregnancy or planning to become pregnant — GLP-1 medications are not approved during pregnancy.
  • Severe gastrointestinal disease — conditions like gastroparesis may be worsened by GLP-1s.
  • BMI below threshold without a qualifying comorbidity — on-label prescribing simply cannot proceed.

How Do Telehealth Rules Differ From an In-Person Visit?

The clinical criteria are identical, but the regulatory environment for telehealth has its own layer. Under COVID-era DEA rules that were extended into 2024, prescribers could issue controlled substances via telemedicine without an in-person visit — but GLP-1 medications are not controlled substances, so they were always permissible via telehealth. The primary legal requirement is that a valid prescriber-patient relationship exists, meaning a licensed clinician must actually review your information and exercise independent medical judgment before signing a prescription. Platforms that auto-generate prescriptions without genuine clinician review violate this standard. When evaluating a platform, look for clear disclosure of who the prescribing clinician is and how they communicate with you.

Frequently Asked Questions

Not always. Many platforms will accept recent labs from your primary care provider. If you have no recent bloodwork, some platforms partner with lab networks so you can get tested locally before the clinician finalizes the prescription. Labs are more likely to be required if you have diabetes, kidney concerns, or the clinician needs to verify a qualifying comorbidity.
Under current FDA labeling for Wegovy and Zepbound, a BMI below 27 does not meet the approved threshold. A clinician could prescribe off-label in rare circumstances, but reputable telehealth platforms generally follow on-label criteria. If your BMI is under 27 and you are concerned about weight, your prescriber can discuss other evidence-based options.
Platforms vary. Some request medical records or insurance EOBs to confirm diagnoses. Others rely on patient attestation, which is legally a declaration you sign. Providing false health information to obtain a prescription is considered fraud and puts your health at risk. Clinicians may also ask follow-up questions if responses seem inconsistent.
A synchronous video visit means you speak in real time with a clinician, similar to a traditional appointment. An asynchronous review means you complete a detailed intake form and the clinician reviews it on their own schedule, then sends a decision via secure message. Both are legally valid ways to establish a prescriber-patient relationship for non-controlled medications like GLP-1s.
Coverage depends entirely on your specific plan, not on whether the prescription came from a telehealth provider or a traditional clinic. Some plans cover Wegovy or Zepbound for obesity with prior authorization; others do not. Mounjaro and Ozempic are more commonly covered when a type 2 diabetes diagnosis is documented. Contact your insurer directly and ask for the prior authorization criteria before starting the process.
Yes, and this is expected practice. You are paying for the clinician's time and medical judgment, not for a guaranteed prescription. A clinician who refuses to deny anyone regardless of medical suitability would be acting unethically. Reputable platforms will explain the reason for denial and may suggest you follow up with a specialist or your primary care provider.
The prescription must still come from a licensed clinician who evaluates you individually — the same legal requirement applies. However, because compounded drugs are not FDA-approved products, they fall under different quality oversight rules. A responsible clinician should explain the distinction between a compounded product and an FDA-approved branded drug so you can make an informed decision.

The information in this article is for educational purposes and reflects FDA labeling and general telehealth practice as of the publication date. It is not a substitute for personalized medical advice. If you are considering a GLP-1 medication, speak with your prescribing clinician or primary care provider about whether it is appropriate for your specific health history, current medications, and goals. They are best positioned to evaluate your individual risk factors and guide your treatment plan.

Sources
  • FDA, 'Wegovy (semaglutide) Prescribing Information', U.S. Food and Drug Administration, 2021
  • FDA, 'Zepbound (tirzepatide) Prescribing Information', U.S. Food and Drug Administration, 2023
  • Kushner RF et al., 'Obesity Pharmacotherapy: An Update', Annual Review of Medicine, 2024
  • Ryan DH and Yockey SR, 'Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over', Current Obesity Reports, 2017
  • U.S. Drug Enforcement Administration, 'DEA Telemedicine Prescribing Rules', DEA / Federal Register, 2023

Keep Reading

Headaches on Semaglutide: What Causes Them and When They StopResearch & News · 6 min readOzempic Burps: Why Sulfur Burps Happen and How to Stop ThemResearch & News · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.